Remedy Entertainment Oyj (REMEDY)
Helsinki Exchange · Finland · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 17.10 |
|---|---|
| 52-week range | 11.06 – 20.65 |
| Return, 1 month / 3 months | −7.0% / +12.9% |
| Return, 1 year / 3 years | +34.4% / −26.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 46 |
| Volatility (1 year) | 42.2% |
| Worst drawdown (1 year) | -32.7% |
| Average daily value traded | 0.31M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Remedy Entertainment is a Finnish video game developer based in Espoo. The studio creates story-driven action games for consoles and personal computers, with a focus on narrative, atmosphere and cinematic presentation. Its catalogue includes the Max Payne games, Alan Wake, Quantum Break and Control, and the company also works on titles connected to those franchises. Remedy develops its own games and partners with publishers to bring them to players around the world.
The shares are listed on the Helsinki Exchange in Finland under the code REMEDY, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Remedy Entertainment Oyj (REMEDY) trades on the Helsinki Exchange in Finland. It last closed at EUR 17.10 on 22 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 49 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 34.4% and over the last three months it rose 12.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Helsinki Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.5% | ||
| From 52-week high | -14.0% | ||
| Momentum | 87 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.9% | ||
| 6-month return | 36.6% | ||
| 12-month return, skipping the last month | 44.5% | ||
| Stability (higher is calmer) | 31 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.7% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 0.31M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.3% |
|---|---|
| 1 month | −7.0% |
| 3 months | +12.9% |
| 6 months | +36.6% |
| 1 year | +34.4% |
| 3 years | −26.0% |
| 5 years | −58.9% |
Signals
| 50-day / 200-day average | 17.94 / 15.07 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.84 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Apr 2023 | EUR 0.1000 |
| 14 Apr 2022 | EUR 0.1700 |
| 15 Apr 2021 | EUR 0.1500 |
| 7 Apr 2020 | EUR 0.1100 |
| 9 Apr 2019 | EUR 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Helsinki Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.